SALT LAKE CITY - Lipocine Inc. (NASDAQ: NASDAQ:LPCN), a biopharmaceutical company with a market capitalization of approximately $24 million, announced today that it will conduct a phase 3 safety and ...
A clinical trial comparing a one-page medication handout proposed by the U.S. Food and Drug Administration (FDA) with an updated version developed by researchers at the University of Pittsburgh that ...